BioStock: Zyneyro’s CEO on the collaboration with CombiGene

At the beginning of the year, CombiGene and Zyneyro entered into a collaboration for the development of new treatments for severe chronic pain conditions. The pain programme COZY consists of a peptide treatment and a gene therapy treatment. The gene therapy is reserved for patients where the possibilities for spontaneous reduction of the pain are considered excluded or unlikely. Zyneyro’s CEO Peter Horn Møller talks with BioStock about the collaboration and overall vision.

Read the full interview with Peter Horn Møller at biostock.se:

https://www.biostock.se/en/2023/05/zyneyros-ceo-on-the-collaboration-with-combigene/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/